UGT1A1
ENSG00000241635
Target class
Enzyme
Chromosome
2
- Chemical probe available
- No
- Other names
- UGT1A
- Target name
- UGT1A1
- Gene name
- UDP glucuronosyltransferase family 1 member A1
- Gene symbol
- UGT1A1
- Protein name
- UDP-glucuronosyltransferase 1A1 (UGT1A1) (EC 2.4.1.17) (Bilirubin-specific UDPGT isozyme 1) (hUG-BR1) (UDP-glucuronosyltransferase 1-1) (UDPGT 1-1) (UGT1*1) (UGT1-01) (UGT1.1) (UDP-glucuronosyltransferase 1A isoform 1)
- UGT1
- GNT1
- Gene biotype
- Protein coding
- Gene family
- UDP glucuronosyltransferases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 7
- Highest tissue expression
- 22.56
- Tissue specificity (Gini)
- 0.913
- Tissue specificity (tau)
- 0.986
- KEGG gene identifiers
- hsa:54658
- Protein interaction confidence
- 0.857464
- Protein interaction partners
- 69
- R-HSA-156588
- R-HSA-189483
- R-HSA-5579002
- R-HSA-9749641
- R-HSA-9753281
- End position
- 233773300
- Start position
- 233760270
- Chromosome
- 2
- Strand
- Forward
- Endoplasmic reticulum membrane
- Single-pass membrane protein . Cytoplasm, perinuclear region .
- PubMed 17179145
- PubMed 17187418
- Tissue specificity (tau)
- 0.9861
- Expression inequality (Gini)
- 0.913051
Expression in transcripts per million
- Liver
- 22.56
- Esophagus - Mucosa
- 4.18
- Small Intestine - Terminal Ileum
- 2.27
- Kidney - Cortex
- 2.2
- Colon - Transverse
- 1.45
Expression in transcripts per million
- Liver22.56
- Esophagus - Mucosa4.18
- Small Intestine - Terminal Ileum2.27
- Kidney - Cortex2.2
- Colon - Transverse1.45
- Bladder1.24
- Skin - Not Sun Exposed (Suprapubic)1.02
- Skin - Sun Exposed (Lower leg)0.99
- Vagina0.94
- Stomach0.81
- Kidney - Medulla0.61
- Testis0.39
- Minor Salivary Gland0.27
- Prostate0.1
- Cervix - Ectocervix0.05
- Thyroid0.04
- Lung0.04
- Adrenal Gland0.02
- Brain - Cortex0
- Brain - Cerebellum0
- Heart - Atrial Appendage0
- Brain - Caudate (basal ganglia)0
- Brain - Putamen (basal ganglia)0
- Esophagus - Gastroesophageal Junction0
- Artery - Tibial0
And 29 more, listed on the interactive page.
- GO:0006789
- GO:0006805
- GO:0008202
- GO:0008210
- GO:0009812
- GO:0019585
- GO:0042167
- GO:0042573
- GO:0045939
- GO:0051552
- GO:0005783
- GO:0005789
- GO:0001972
- GO:0004857
- GO:0005496
- GO:0005515
- GO:0015020
- GO:0019899
- GO:0042803
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_UGT1A1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated metabolism.
- cell-based: LTEA_HepaRG_UGT1A1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated metabolism.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (752)
- "The Once A Day Protease Inhibitor Regimens"
- 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
- A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
- A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
- A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
- A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir